$1.16 Billion is the total value of Redmile Group, LLC's 50 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 43.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARRY | Sell | ARRAY BIOPHARMA INC | $146,079,000 | +29.9% | 16,618,776 | -0.2% | 12.59% | +40.8% |
| SGEN | Sell | SEATTLE GENETICS INC | $80,258,000 | -16.6% | 1,520,904 | -14.6% | 6.92% | -9.6% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $71,976,000 | -2.6% | 1,620,355 | -21.0% | 6.20% | +5.5% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $61,286,000 | -35.1% | 12,331,130 | -3.3% | 5.28% | -29.6% |
| INCY | Sell | INCYTE CORP | $45,321,000 | -19.6% | 451,987 | -24.4% | 3.91% | -12.8% |
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $40,908,000 | -43.5% | 366,068 | -32.9% | 3.53% | -38.8% |
| PRTA | Sell | PROTHENA CORP PLC | $32,157,000 | -23.6% | 653,725 | -6.8% | 2.77% | -17.2% |
| NSTG | Sell | NANOSTRING TECHNOLOGIES INC | $20,916,000 | -15.4% | 937,957 | -24.2% | 1.80% | -8.3% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $15,214,000 | +2.1% | 832,736 | -9.2% | 1.31% | +10.6% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $9,939,000 | -61.1% | 459,505 | -57.2% | 0.86% | -57.8% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $7,660,000 | -31.6% | 696,992 | -2.5% | 0.66% | -25.9% |
| MODN | Sell | MODEL N INC | $7,168,000 | -58.4% | 809,914 | -47.8% | 0.62% | -54.9% |
| ELGX | Sell | ENDOLOGIX INC | $6,903,000 | -84.5% | 1,206,894 | -65.3% | 0.60% | -83.2% |
| WOOF | Sell | VCA INC | $4,808,000 | -24.5% | 70,040 | -23.0% | 0.41% | -18.2% |
| SPNC | Sell | SPECTRANETICS CORP | $4,597,000 | -45.3% | 187,627 | -43.9% | 0.40% | -40.7% |
| FATE | Sell | FATE THERAPEUTICS INC | $3,562,000 | -19.9% | 1,419,058 | -0.4% | 0.31% | -13.3% |
| AUPH | Sell | AURINIA PHARMACEUTICALS INC | $77,000 | -86.4% | 36,743 | -80.4% | 0.01% | -84.4% |
| AKAOQ | Exit | ACHAOGEN INC | $0 | – | -32,300 | -100.0% | -0.01% | – |
| DXCM | Exit | DEXCOM INC | $0 | – | -2,460 | -100.0% | -0.02% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -677 | -100.0% | -0.02% | – |
| HUM | Exit | HUMANA INC | $0 | – | -1,390 | -100.0% | -0.02% | – |
| FBT | Exit | FIRST TR EXCHANGE TRADED FDny arca biotech | $0 | – | -3,090 | -100.0% | -0.02% | – |
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -27,539 | -100.0% | -0.06% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -336,759 | -100.0% | -0.41% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -45,410 | -100.0% | -0.44% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -408,462 | -100.0% | -0.52% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -288,356 | -100.0% | -0.75% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -916,927 | -100.0% | -1.66% | – |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -505,154 | -100.0% | -1.85% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -640,400 | -100.0% | -3.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.